UK drug chiefs issue alert on ANOTHER frightening risk of weight loss jabs - drugs raise risk of people choking to death
The Medicines and Healthcare Products Regulatory Agency (MHRA) has ruled that warnings about the risk should now be added to ...
BMJ2h
GLP-1 agonists may raise risk of pulmonary aspiration during surgery, MHRA warns
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as semaglutide (Wegovy and Ozempic) and tirzepatide (Mounjaro) may ...
Novo Nordisk's SWOT analysis: stock outlook amid GLP-1 market growth
A/S, a global healthcare company specializing in diabetes care and other chronic conditions, has been at the forefront of the rapidly expanding GLP-1 market. With a market capitalization of $376.79 ...
BioPharma Dive22h
FDA clears use of Ozempic to protect kidney health
The approval adds a new indication for GLP-1 drugs and gives Novo an advantage over Lilly’s rival diabetes drug Mounjaro, ...
Healio22h
Increase in online searches for obesity drugs correlates with rise in prescriptions
The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with ...
Josh Gad reveals he had to stop taking weight-loss drug due to side effects: ‘Really bummed out’
The actor said he lost 40 pounds taking GLP-1 medication before a negative side effect necessitated a change to a different ...
Knowridge15h
Diabetes and obesity can damage the liver to the point of failure – but few people know their risk of developing liver disease
Metabolic dysfunction-associated steatotic liver disease, or MASLD, is an umbrella term describing conditions related to a ...
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...